Castro, Francesca http://orcid.org/0000-0003-2023-5483
Parikh, Richa http://orcid.org/0000-0002-5270-104X
Eustaquio, Jelyn C. http://orcid.org/0009-0009-1965-098X
Derkach, Andriy
Joseph, Janine M. http://orcid.org/0000-0003-3948-2070
Lesokhin, Alexander M. http://orcid.org/0000-0001-9321-702X
Usmani, Saad Z. http://orcid.org/0000-0002-5484-8731
Shah, Urvi A. http://orcid.org/0000-0001-8419-1091
Article History
Received: 7 July 2023
Revised: 15 December 2023
Accepted: 19 December 2023
First Online: 29 December 2023
Competing interests
: UAS reports research funding support from Celgene/BMS, Janssen, Plantable, Sabinsa pharmaceuticals, VeggieDoctor and M and M labs to the institution, non-financial research support; personal fees from ACCC, MashUp MD, Janssen Biotech, Sanofi, BMS, MJH LifeSciences, Intellisphere, Phillips Gilmore Oncology Communications, i3 Health and RedMedEd outside the submitted work. AML reports grants from Bristol Myers Squibb and Genentech; grants, personal fees, and non-financial support from Pfizer; and grants and personal fees from Janssen outside the submitted work. AML has a patent for US20150037346A1 licensed and with royalties paid from Serametrix, Inc. SZU reports grants/personal fees from Amgen, Celgene, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDx, Netherlands; Merck, and GSK; grant funding from Bristol Myers Squibb and Pharmacyclics; and personal fees from AbbVie, MundiPharma, Gilead, Genentech, and Oncopeptides. No disclosures were reported by the other authors.